ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Why is important to cross your I&T

<< Previous

Bullboard Posts

Next >>

Comment by retiredcopon Jun 10, 2021 11:17pm

158 Views

Post# 33370458

RE:Why is important to cross your I&T

Well said mole... very important for PMN .. we are a company that is possiby going to NASDQ.. the last thing we would need is a regulatory warning or sanction from HC or FDA even if it is something our JV partner intiated on their own ... I always read that sign at my mechanis shop... if you want it done right it will cost more and it will take longer..if you want it cheaper it will be done quicker and poorer quality.

<< Previous

Bullboard Posts

Next >>

5 steps to mastering risk management in the stock market